CHICAGO, Dec. 3, 2019 /PRNewswire/ -- According to the new market research report "Blood Screening Market by Technology (Nucleic Acid Amplification, (Real Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2024", published by MarketsandMarkets™, the Blood Screening Market is projected to reach USD 3.3 billion by 2024 from USD 2.2 billion in 2019, at a CAGR of 8.7%.
Download PDF Brochure:
The increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are the key factors driving the growth of this market.
The reagents & kits segment accounted for the largest share of the Blood Screening Market, by product & service, in 2018
Based on product & service, the market is segmented into reagents and kits, instruments, and software and services. The reagents and kits segment accounted for the largest share of the market in 2018. The large share of this segment can be attributed to the high consumption and repeated use of reagents & kits in blood screening procedures. Also, the accessibility of a wide range of reagents and the need for reliable, specific, and fast detection of TTIs are driving the growth of the blood screening reagents & kits market.
Browse in-depth TOC on "Blood Screening Market"
177 – Tables
37 – Figures
166 – Pages
Blood banks segment to register the highest growth rate during the forecast period
Based on end users, the Blood Screening Market is segmented into blood banks and hospitals. The blood bank segment accounted for the larger market share in 2018 and is projected to witness a higher growth rate during the forecast period. This can be attributed to the increasing demand for donated blood, a growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, an increasing number of donations worldwide, and growth in government funding to charitable trusts.
Get 10% Customization on this Research Report:
North America is the largest regional market for blood screening
Based on region, the Blood Screening Market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2018, North America accounted for the largest market share, followed by Europe. Factors such as the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the market in North America.
The prominent players operating in the Blood Screening Market include Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMérieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US) ,Ortho Clinical Diagnostics, Inc.(US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt. Ltd (India).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Get Special Pricing on Bundle Reports:
Browse Related Reports:
Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software), Technology (ELISA, Rapid Test), Platform (Radioimmunoassay), Specimen, Application (Infectious Diseases, Oncology, Cardiology), End User (Hospitals) – Global Forecast to 2023
Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laboratory), Product & Service (Reagent, Software) - Global Forecast to 2023
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/blood-screening-market.asp
Visit Our Website: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/blood-screening.asp